Citations

Clear

590 citation(s) found for "Ho, Ben".

Bloating and Distention Patients Form 6 Distinct Latent Clusters Based on Symptoms, Diet, Psychosocial, and Quality-of-Life Parameters
Byale, Anjali , Simrén, Magnus , Tack, Jan , Nevé, Boris Le , Hassouna, Rim , Bangdiwala, Shrikant I. , Drossman, Douglas A. , Grover, Madhusudan , Palsson, Olafur S , Simrén, Magnus , Tack, Jan , Le Nevé, Boris , Hassouna, Rim , Bangdiwala, Shrikant , Sperber, Ami D , Drossman, Douglas , Grover, Madhusudan , Palsson, Olafur S.

Mayo Clinic

American Journal of Gastroenterology | July 2, 2025 | Volume: 121 | Issue: 3 | Pages: 754-766

10.14309/ajg.0000000000003622 | PMID 40600966 Get It

INTRODUCTION: Bloating, distention, and gas-related gastrointestinal (GI) symptoms are frequently reported by patients across the spectrum of disorders of gut-brain interaction (DGBI). We aimed to characterize these using latent class modeling in a large multinational survey. METHODS: A nationwide survey of adults in the United States, United Kingdom, and Mexico used quota sampling for demographic balance. It included Rome IV diagnostic questions, Intestinal Gas Questionnaire, Patient Health Questionnaires for anxiety and depression (PHQ-4) and somatization (PHQ-12), quality of life (PROMIS Global-10), and lifestyle questions. Latent class analysis was performed using “depmix” in RStudio 4.2.3. RESULTS: A total of 3,471 subjects experiencing bloating and/or distention (mean age 43 years, 57% female) were included. Using 42 demographic and pertinent clinical variables, latent class analysis revealed 6 distinct clusters. The first 2 clusters demonstrated limited-to-moderate impairment in health-related quality of life (HRQoL), with both characterized by some degree of dietary and supplement associations; however, cluster 2 lacked specific triggers observed in other clusters. The subsequent 2 clusters showed favorable HRQoL and mild gas-related symptoms, with only cluster 4 exhibiting distinct dietary triggers. The final 2 clusters, associated with bowel dysfunction, showed a higher prevalence of irritable bowel syndrome (IBS) with constipation and IBS mixed in cluster 5, and IBS with diarrhea in cluster 6. These bowel dysfunction clusters exhibited severe gas symptoms in the preceding 24 hours and greater HRQoL impairment compared with the other 4 clusters. Notably, cluster 5 was linked to dietary triggers, whereas cluster 6 was defined by psychosocial comorbidities. DISCUSSION: Bloating and distention patients are likely driven by variable influences of dietary, psychological, and bowel dysfunction. Further studies are needed to identify mechanisms and titrate treatment suited to specific mechanistic drivers.
Genomic dimensions deconstruct the clinical heterogeneity of bipolar disorder
Veen, Tracey van der , Tesfaye, Markos , Yang, Jessica , Boltz, Toni , David, Friederike S. , Crinion, Shane , Koromina, Maria , Bigdeli, Tim B., Coombes, Brandon J., Panagiotaropoulou, Georgia, Parker, Nadine, Sung, Heejong , Bass, Nicholas, Coleman, Jonathan R. I., Guzman-Parra, José , Kálmán, János , McGrouther, Caroline C., Rangan, Aaditya V. , Scott, Katie , Vreeker, Annabel , Bauer, Michael , Brunkhorst-Kanaan, Nathalie, Byerley, William , Cervantes, Pablo , Chatzinakos, Chris , Claus, Isabelle , Cruceanu, Cristiana , Cuellar-Barboza, Alfredo, Dafnas, Konstantinos , Degenhardt, Franziska, Fanous, Ayman H. , Ferrier, I. Nicol , Forty, Liz , Frank, Josef , Freimer, Nelson B. , Hamshere, Marian L., Harder, Arvid , Hautzinger, Martin , Hellgren, Dennis, Hoffmann, Per, Jönsson, Lina , Kittel‐Schneider, Sarah , Knowles, James A. , Lavebratt, Catharina , Lawrence, Jacob , Leber, Markus , Lucae, Susanne , Lundberg, Martin , Maier, Wolfgang , Maihofer, Adam X. , Maratou, Eirini , McKay, James , Medeiros, Helena , Meyer‐Lindenberg, Andreas , Moutsatsou, Paraskevi , Mühleisen, Thomas W. , O’Connell, Kevin S. , Papiol, Sergi , Perry, Amy , Pisanu, Claudia , Potash, James B. , Rapaport, Mark Hyman , Regeer, Eline J. , Rice, John P. , Schulte, Eva C. , Senner, Fanny , Shilling, Paul D. , Sirignano, Lea , Slaney, Claire , Smeland, Olav B. , Sobell, Janet L. , Stein, Dan J. , Vawter, Marquis P. , Vedder, Helmut , Witt, Stephanie H. , Zandi, Peter P. , Investigators, Genomic Psychiatry Cohort (GPC), Psychiatry, HUNT All-In, Bengesser, Susanne , Berrettini, Wade H. , Blackwood, Douglas, Boehnke, Michael , Catts, Stanley V. , Craddock, Nicholas , Dikeos, Dimitris , Ferentinos, Panagiotis , Frye, Mark A. , Gawlik, Micha , Kahn, René S., Landén, Mikael , Lenger, Melanie , Loughland, Carmel , Melle, Ingrid , Myers, R , Müller‐Myhsok, Bertram , Neale, Benjamin M. , Øedegaard, Ketil J. , Paciga, Sara A. , Pato, Carlos N. , Pawlak, Joanna , Perlis, Roy H. , Reif, Andreas , Schalling, Martin , Scott, Laura J. , Scott, Rodney J., Stahl, Eli A. , Stordal, Eystein , Sullivan, Patrick F., Vaaler, Arne E. , Waldman, Irwin D. , Ophoff, Roel A. , Mullins, Niamh , Forstner, Andreas J. , van der Veen, Tracey , Yang, Jessica Mei Kay , Alda, Martin , Ophoff, Roel A , O'Connell, Kevin S , Mullins, Niamh , Forstner, Andreas J , Grigoroiu-Serbanescu, Maria , Edenberg, Howard J , McMahon, Francis , Andreassen, Ole A , Di Florio, Arianna , McQuillin, Andrew , Witt, Stephanie H , Meyer-Lindenberg, Andreas , Stein, Dan J , Papiol, Sergi , Cruceanu, Cristiana , Schulte, Eva , Kittel-Schneider, Sarah , Lavebratt, Catharina , Pisanu, Claudia , Reif, Andreas , Perlis, Roy H , Andlauer, Till F. M. , Bigdeli, Tim B. , Coombes, Brandon J. , Greenwood, Tiffany A. , Panagiotaropoulou, Georgia , Parker, Nadine , Bass, Nicholas, Coleman, Jonathan Ri , Mitchell, Brittany L. , Shadrin, Alexey A. , Smith, Daniel J. , Adorjan, Kristina , Albani, Diego , Alemany, Silvia , Alliey‐Rodriguez, Ney , Antoniou, Anastasia , Beins, Eva Carolina , Boks, Marco P. , Bosch, Rosa , Brumpton, Ben , Budde, Monika , Cabana‐Domínguez, Judit , Cairns, Murray J. , Carpiniello, Bernardo , Casas, Miguel , Clarke, Toni‐Kim , Cuéllar‐Barboza, Alfredo B. , Czerski, Piotr M. , Dale, Anders M. , Dalkner, Nina , DePaulo, J Raymond , Djurovic, Srdjan , Escott‐Price, Valentina , Fellendorf, Frederike T. , Frei, Oleksandr , Garnham, Julie , Gizer, Ian R. , Gordon, Scott D. , Gordon‐Smith, Katherine , Hahn, Tim , Hamshere, Marian L. , Heilbronner, Urs , Herms, Stefan , Hickie, Ian Bernard , Hoffmann, Per , Holmans, Peter , Jamain, Stéphane , Kennedy, James L. , Koch, Elise , Kogevinas, Manolis , Kranz, Thorsten M. , Kushner, Steven A. , Lind, Penelope A. , Lundberg, Martin, MacIntyre, Donald J. , Malaspina, Dolores , Manchia, Mirko , Martinsson, Lina , McInnis, Melvin G. , Millischer, Vincent , Morris, Derek W. , Olsen, Catherine M. , Pardiñas, Antonio F. , Pfennig, Andrea , Quested, Digby J. , Rivera, Margarita , Sindermann, Lisa , Siskind, Dan , Artigas, María Soler , Stein, Frederike , Świątkowska, Beata , Thorp, Jackson G. , Toma, Claudio , Tondo, Leonardo , Tooney, Paul A. , Walters, James , Young, Allan H. , Zillich, Lea , Adolfsson, Rolf , Alfredsson, Lars , Backlund, Lena , Baune, Bernhard , Bellivier, Frank , Biernacka, Joanna M. , Blackwood, Douglas , Breen, Gerome , Carr, Vaughan J , Cichon, Sven , Corvin, Aiden , Dannlowski, Udo , Esko, Tõnu , Étain, Bruno , Fullerton, Janice M. , Gershon, Elliot S. , Goes, Fernando , Green, Melissa J. , Hauser, Joanna , Henskens, Frans A , Hjerling‐Leffler, Jens , Jones, Ian Richard , Jones, Lisa Anne , Kahn, René S. , Kelsoe, John R , Kircher, Tilo , Kirov, George , Kobayashi, Nene, Leboyer, Marion , Li, Qingqin S. , Lissowska, Jolanta , Loughland, Carmel M. , Luykx, Jurjen J. , Martin, Nicholas G. , Mathews, Carol A. , Mayoral, Fermín , McElroy, Susan L. , McIntosh, Andrew M. , Medland, Sarah E. , Mitchell, Philip B , Morken, Gunnar , Möser, Chiara, Nievergelt, Caroline M , Nurnberger, John I , Nöthen, Markus M. , O‘Donovan, Michael , Olsson, Tomas , Owen, Michael J. , Pantelis, Christos , Pato, Michele T. , Patrinos, George P. , Ramos‐Quiroga, Josep Antoni , Reininghaus, Eva , Ribasés, Marta , Rietschel, Marcella , Ripke, Stephan , Rouleau, Guy Armand , Schall, Ulrich , Schofield, Peter R. , Schulze, Thomas , Scott, Rodney J. , Serretti, Alessandro , Smoller, Jordan W. , Squassina, Alessio , Streit, Fabian , Turecki, Gustavo , Vieta, Eduard , Vincent, John B. , Weickert, Cynthia Shannon , Weickert, Thomas Wesley , Whiteman, David C. , Alda, Martin , Grigoroiu‐Serbânescu, Maria , McMahon, Francis J. , Andreassen, Ole A. , McQuillin, Andrew

Mayo Clinic

No container title available | June 25, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1101/2025.06.23.25330155 | PMID 40666370 Get It

ABSTRACT Bipolar disorder’s (BD) clinical heterogeneity has an unresolved genetic basis. We meta-analyzed genome-wide association studies (GWAS) of 16 BD subphenotypes in 226,032 individuals from 57 cohorts (38,022 cases); 10 advanced to multivariate and multi-trait analyses. Four factors (compulsive, psychotic, dysregulated, internalizing) explained 82.8% of shared genetic variance. BD1 and BD2 loaded on distinct factors despite a high genetic correlation; 87.0% of common-factor loci were significant in neither subtype. Unipolar mania aligned with psychosis over internalizing, and was distinguishable from BD1, and rapid cycling showed heritable cross-domain liability. We identified 356 risk loci, 158 novel, including the first univariate-GWAS associations for psychosis, unipolar mania, rapid cycling and schizoaffective disorder—and 249 credible genes (89 high-confidence), 12 with approved-drug or clinical-phase annotations. Cell-type association showed a midbrain dopaminergic–GABAergic gradient along the psychotic factor. BD’s genetic architecture appears hierarchical—a general liability resolving into dimensions of course and comorbidity beyond diagnostic subtypes.
P57 Efficacy of risankizumab versus ustekinumab by disease duration in moderate-to-severe crohn’s disease: phase 3 SEQUENCE post-hoc analysis
Peyrin-Biroulet, Laurent, Ben‐Horin, Shomron, Ha, Christina , Aponte, Fernando, Kligys, Kristina, Zambrano, Javier , Anschutz, Toni , Garrison, Andrew, Peyrin‐Biroulet, Laurent , Ben‐Horin, Shomron , Siegmund, Britta , Colombel, Jean‐Frédéric

Mayo Clinic

Posters | June 23, 2025 | Volume: No volume available | Issue: No issue available | Pages: A123.2-A124

10.1136/gutjnl-2025-bsg.193 Get It

Recent-onset atrial fibrillation: challenges and opportunities
Svennberg, Emma , Andrade, Jason G. , Anselmino, Matteo , Biton, Yitschak , Brandes, Axel , Buckley, Claire , Espuny, Josep Lluis Clua , Doehner, Wolfram , Domínguez, Helena , Fauchier, Laurent , Glotzer, Taya V. , Hendriks, Jeroen , Hills, Mellanie True , Hindricks, Gerhard , Joung, Boyoung , Levin, Lars‐Åke , Liu, Shaowen , Lobban, Trudie , Macfarlane, Peter W. , Mairesse, Georges H. , Marcus, Gregory M. , Orchard, J. , Reiffel, James A. , Siontis, Konstantinos C. , Stavrakis, Stavros , Svendsen, Jesper Hastrup , Teh, A. , Tieleman, Robert G , Camm, A. John , Freedman, Ben , Andrade, Jason G , Anselmino, Matteo , Biton, Yitschak , Boriani, Giuseppe , Brandes, Axel , Buckley, Claire , Cameron, Alan C , Lluis Clua Espuny, Josep , Crijns, Harry J G M , Diederichsen, Søren Z , Doehner, Wolfram , Dominguez, Helena , Duncker, David , Fauchier, Laurent , Glotzer, Taya , Guo, Yutao , Haeusler, Karl G , Haim, Moti , Healey, Jeffrey S , Hendriks, Jeroen M , True Hills, Mellanie , Hindricks, Gerhard , Hobbs, F D Richard , Johnson, Linda S B , Joung, Boyoung , Kamel, Hooman , Kirchhof, Paulus , Lane, Deirdre A , Levin, Lars-Åke , Lip, Gregory Y H , Liu, Shaowen , Lobban, Trudie , Macfarlane, Peter W , Mairesse, Georges , Marcus, Gregory M , Noseworthy, Peter A , Ntaios, George , Orchard, Jessica J , Passman, Rod , Reidpath, Daniel D , Reiffel, James A , Ribeiro, Antonio Luiz , Rivard, Lena , Sanders, Prashanthan , Sandhu, Roopinder K , Schnabel, Renate B , Siontis, Konstantinos C , Sposato, Luciano A , Stavrakis, Stavros , Steinhubl, Steven , Svendsen, Jesper Hastrup , Teh, Andrew W , Themistoclakis, Sakis , Tieleman, Robert G , Camm, Alan John , Freedman, Ben , Boriani, Giuseppe , Cameron, Alan C. , Crijns, Harry J.G.M. , Diederichsen, Søren Zöga , Duncker, David , Haim, Moti , Healey, Jeff S. , Hobbs, Richard , Johnson, Linda S.B. , Kamel, Hooman , Kirchhof, Paulus , Lane, Deirdre A. , Noseworthy, Peter A. , Passman, Rod , Rivard, Léna , Sanders, Prashanthan , Schnabel, Renate B. , Sposato, Luciano A. , Tieleman, RG

Mayo Clinic

European Heart Journal | June 23, 2025 | Volume: 47 | Issue: 2 | Pages: 170-187

10.1093/eurheartj/ehaf478 | PMID 40873195 Get It

Abstract Atrial fibrillation (AF) is increasingly diagnosed early, close to its first occurrence due to: (i) increased public awareness with self-screening; (ii) health care initiatives including population screening and opportunistic case finding; and (iii) increased use and surveillance of implantable cardiac devices. At its onset, AF is often low burden, and cardiovascular co-morbidities may be absent or at an early stage. Thus, the management of recent-onset AF has become an issue of growing importance. Professional guidelines have traditionally focused on anticoagulant thromboprophylaxis, generally recommending a cautious approach to rhythm control, and priority has been given to rate control to alleviate symptoms. In recent guidelines, the importance of managing lifestyle and co-morbidities has increased. The AF-SCREEN collaboration proposes that a vigorous approach to active management of recent-onset AF may be warranted. This includes addressing co-morbidities and promoting healthy lifestyles to prevent the emergence or progression of AF and associated cardiovascular disease, as well as the initiation of active rhythm control ± anticoagulation to prevent AF-related morbidity and mortality, including stroke and heart failure (HF). Intuitively, intervention early after AF onset would be beneficial since lifestyle and co-morbidity management, plus rhythm control and anticoagulation, are important contributors to improved outcomes in patients with established AF, but robust evidence is lacking for recent-onset AF. There is a delicate balance between achieving favourable outcomes such as preventing strokes, HF and AF progression vs the complications and potential adverse effects of interventions. Given the serious long-term consequences, innovative approaches are necessary to determine the value and risks of initiating active therapy very early in the course of AF. More data are needed to guide the best management of recent-onset AF, bearing AF burden in mind. Long-term studies using large national databases linked to electronic medical records and rhythm monitoring devices offer excellent opportunities. Shorter-term studies focusing on reducing AF burden to slow AF progression and studies focusing on outcomes such as HF could be used in both randomized clinical trials and observational cohort studies.
Insomnia symptoms amongst those with acute post‐traumatic headache attributed to mild traumatic brain injury
Braunecker, Ben J. , Smith, Dani, Chong, Catherine D. , Dodoo, Christopher A, Chong, Catherine D , Braunecker, Ben J. , Dodoo, Christopher , Schwedt, Todd J.

Mayo Clinic

Headache: The Journal of Head and Face Pain | June 11, 2025 | Volume: 65 | Issue: 9 | Pages: 1565-1572

10.1111/head.14971 | PMID 40497559 Get It

AbstractBackgroundPrevious publications have described the presence and severity of insomnia amongst those with persistent post‐traumatic headache (PPTH), but there has been a paucity of studies investigating insomnia during the acute phase of post‐traumatic headache (APTH). The primary study objective was to investigate insomnia symptoms and their severity in individuals with APTH due to mild traumatic brain injury (mTBI), and the secondary objective was to assess how psychological factors, sensory hypersensitivities, headache burden, and cognitive performance might associate with insomnia.MethodsIn this clinic‐based, cross‐sectional study, 82 individuals with APTH due to mTBI and 82 healthy controls (HC) were included. Participants completed the Insomnia Severity Index (ISI), Trail Making Test (TMT A and B), 12‐item Allodynia Symptom Checklist (ASC‐12), State–Trait Anxiety Inventory, Photosensitivity Assessment Questionnaire (PAQ), Beck Depression Inventory (BDI), Hyperacusis Questionnaire (HQ), Rey Auditory Verbal Learning Test (RAVLT), and a detailed headache characteristics questionnaire within 59 days of their mTBI to assess insomnia severity, psychological features, sensory hypersensitivities, headache symptoms, and cognitive performance. The questionnaire and test results were compared between APTH and HC groups. Within the APTH group, ISI scores were correlated with the other assessments to determine underlying clinical relationships.ResultsParticipants with APTH, evaluated an average of 27.2 days after their mTBI, had significantly higher ISI scores (median [interquartile range, IQR] score 12 [6–17]) compared to HC (0 [1.3–6], p < 0.001). Twenty‐four (29%) individuals with APTH had ISI scores categorized as moderate clinical insomnia compared to two (2%) in the HC group. Additionally, seven (9%) in the APTH group and none of the HC had ISI scores indicative of severe clinical insomnia. Those with APTH significantly differed from the HC on the BDI (median [IQR] score APTH: 9 [5–16.8] vs. HC: 2 [0–4]; p < 0.001), state anxiety (median [IQR] score APTH: 36.5 [26–45] vs. HC: 23 [20–27.5]; p < 0.001), trait anxiety (median [IQR] score APTH: 38 [27.3–46.8] vs. HC: 26 [23–30]; p < 0.001), photosensitivity (median [IQR] PAQ score APTH: 2 [1–4] vs. HC: 0 [0–1]; p < 0.001), allodynia (median [IQR] ASC‐12 score APTH: 2 [0–5.8] vs. HC: 0 [0–0], p < 0.001), hyperacusis (median [IQR] HQ score APTH: 15.5 [7–23] vs. HC: 4 [2.3–7], p < 0.001), and RAVLT‐delayed recall (median [IQR] score APTH: −0.8 [−1.5 to 0] vs. HC: −0.1 [−0.9 to 0.7], p = 0.019). For participants with APTH, the ISI was most significantly associated with the BDI (standardized regression coefficient (RC) [95% confidence interval, CI] 0.68 [0.52–0.84], p < 0.001), followed by state anxiety (RC [95% CI] 0.60 [0.42–0.78], p < 0.001), trait anxiety (RC [95% CI] 0.56 [0.37–0.74], p < 0.001), headache severity (RC [95% CI] 0.40 [0.19–0.60], p < 0.001), HQ (RC [95% CI] 0.36 [0.16–0.57], p = 0.001), and PAQ (RC [95% CI] 0.35 [0.15–0.56], p = 0.001).ConclusionsIndividuals with APTH have more symptoms of insomnia compared to HC with 38% of individuals with APTH experiencing moderate or severe insomnia symptoms. Insomnia symptoms may be associated with more severe depression, anxiety, photophobia, hyperacusis, headache severity, and cognitive impairment. To address the overall well‐being of patients with APTH, clinicians should screen for and appropriately manage insomnia along with other symptoms following mTBI.
Tumor Treating Fields With Gemcitabine and Nab-Paclitaxel for Locally Advanced Pancreatic Adenocarcinoma: Randomized, Open-Label, Pivotal Phase III PANOVA-3 Study
Babiker, Hani M. , Picozzi, Vincent J. , Chandana, Sreenivasa R , Melichar, Bohuslav, Kasi, Anup , Gang, Jin, Gállego, Javier , Bullock, Andrea J. , Chunyi, Hao, Hitre, Erika, Osipov, Arsen , Alés, Inmaculada, Dragovich, Tomislav, Lee, Woo Jin , Feeney, Kynan, Ueno, Makoto , Seufferlein, Thomas , Investigators, on behalf of the PANOVA-3 Study, Osipov, Arsen, Matrana, Marc , Blondin, Nicholas, Shroff, Rachna T. , Orr, Douglas, Anderson, Michael J. , Shields, Anthony F. , Hamm, John , Bullock, Andrea, Nagireddy, Sumana, Kolodney, Joanna, Dragovich, Tomislav, Maniam, Ajit, Sears, Judith D., Stilwill, Joseph, Cusnir, Mike , Niewiaroska, Anna, Small, William, Kasi, Anup, Tache, Jason, Ross, Sharona, Shihabi, Samer, Gandhi, Sunil, Reeves, J. N. , Green, Garrett , Feinstein, Trevor, Huyck, Timothy K., Ramdin, Nadia, Marsh, Robert , Jiang, Yixing , Hatoum, Hassan , Manda, Sudhir, Kochenderfer, Mark D., Illum, Henrik, Richards, Donald , Valilis, P., Wong, Lucas, Newton, Herbert B. , Abdelrahim, Maen, Einspahr, David, Siegel, Richard, McKenney, Scott, Narang, Mohit , Cárdenes, Higinia R. , Thanikachalam, Kannan , Raff, Joshua P. , Ye, Joseph , Behl, Deepti , Kam, Audrey E., DeRose, Paul, Tasneem, A. , Brenner, Warren, Santos, Jennifer De Los , Rausch, D C, Trikha, Gaurav, Gabrail, Nashat , Mowat, Rex B., Jahangir, Khawaja, Schumaker, Robert P. , Soffen, Edward , Bravin, Eric, Gupta, Mukul Kumar , Bedoya-Apraez, Ivan Dario, Kang, Tyler Y., Lemay, Frédéric , Vincent, Mark , Létourneau, Richard, Doehring, Christine, Haberkorn, Mike, Rußwurm, Karen, Chater, Jack, Küng, Marc , Schacher, Sabine, Passhak, Maria , Geva, Ravit , Hubert, Ayala, Golan, Talia , Senellart, Hélène, Trouilloud, Isabelle , Blan, Jean-Frederic, Dourthe, Luis-Marie, Roy, Florence Le, Martin-Babau, J., Greil, Richard , Schreil, Georg, Gerger, Armin , Eisterer, Wolfgang , Mercadé, T. Macarulla, Cubillo, Antonio , Pons, Francesc Valladares, Díaz, Inmaculada Alés, Rivera, Fernando , Sarvise, Mariano Ponz, Airoldi, Mario , Bellotti, Giovanna, Corsi, Domenico , Antonuzzo, Lorenzo , Melichar, Bohuslav, Holečková, Petra , Kotasek, Rostislav, Němeček, Radim , Cutsem, Eric van, Laethem, Jean‐Luc Van , Sym, Sun Jin , Kim, Jin Young , Oh, Sang Cheul , Park, Joon Oh, Kim, Jin Won , Lee, Myung Ah , Choi, Hye Jin, Kang, Seok Yun , Mruk, Andrzej, Freier, Beata, Kosakowska, Ewa Anna, Kocsis, Judit, Csőszi, Tibor , Hitre, Erika, Al-Farhat, Yousuf, Cang, Shundong , Jin, Gang , Zuo, Changzeng, Song, Lijie, Wu, Zheng , Gao, Jie , Zhang, Tao� , Wang, Yusheng , Yuan, Xin , Li, Zhi-Hua , Chen, Rufu , Cai, Xiujun , Zhu, Zhizhen, Bai, Yuxian , Bai, Chunmei, Yau, Thomas, Joubert, Warren , Wong, Ka Yeung Mark, Harris, Marion , Mišir, Ana, Faccio, Adilson , Cruz, Felipe Melo , Azevedo, Srergio De, Victorino, Ana Paula , Paiva, Tadeu Ferreira, Franke, Fábio , Tiscoski, Katsuki Arima , Parolla, Gabriel, Lilno, Flora, Siqueira, Mariana Bruno , Lyra, Marcos, Lira, Jose Luis Martinez, Oliva, Dolores Mendoza, Vazquez, Arturo, Luviano, Jesus Elvis Cabrera, Gutiérrez, Erika Castillo , Camargo, Vanessa Rosas, Guerra, Cristian Chavez, Flores, Osvaldo Hernandez, Contreras, Jessica Reyes, Villanueva, Ángel Gómez, Villanueva, Omar Zayas, Bullock, Andrea , Wyrwicz, Lucjan , Osipov, Arsen , De La Fouchardiere, Christelle , Lee, Woojin , Ueno, Makoto , Van Cutsem, Eric , Macarulla, Teresa , Babiker, Hani , Antonuzzo, Lorenzo , Melichar, Bohuslav, Kasi, Anup , Gang, Jin, Gallego, Javier , Hitre, Erika, Fouchardière, Christelle de la , Dragovich, Tomislav, Philip, Philip A. , Cutsem, Eric Van , Macarulla, Teresa , Investigators, on behalf of the PANOVA-3 Study, Spigel, David R. , Osipov, Arsen, Lou, Emil , Bullock, Andrea, Dragovich, Tomislav, Coveler, Andrew L. , Arena, Francis P. , Kasi, Anup, Ross, Sharona , Reeves, James, Green, Garrett, Uemura, Marc Isamu , Ye, Joseph, Wang, James Z. , Rausch, Daniel, Park, Jae‐Hyun , Schumaker, Robert, Gupta, Mukul, Letourneau, Richard, Fuchs, Martin , Vogel, Arndt , Chater, Jack, Schacher, Sabine, Stemmer, Salomon M. , Dourthe, Luis-Marie, Abdelghani, Méher Ben , Pons, Francesc Valladares, Guillén‐Ponce, Carmen , Yayá, Ricardo , Ponz‐Sarvisé, Mariano , Vincenzi, Bruno , Melichar, Bohuslav, Petruzelka, Lubos B. , Cutsem, Eric van, Borbath, Ivan , Hwang, Jun‐Eul , Oh, Sung Yong , Lee, Moon Hee , Choi, Hye Jin , Chon, Hong Jae , Ramlau, Rodryg , Mruk, Andrzej, Hitre, Erika, Bassam, Ali, Hao, Chunyi , Liang, Bo , Li, Wei , Bai, Chunmei , Joubert, Warren, Marx, Gavin M. , Azevedo, Srergio De, Hoff, Paulo M. , Vazquez, Arturo, Guerra, Cristian Chavez, Cortez, David Orta, Campos-Gómez, Saúl , Espinoza, Iván Romarico González

Mayo Clinic

Journal of Clinical Oncology | May 31, 2025 | Volume: 43 | Issue: 21 | Pages: 2350-2360

10.1200/jco-25-00746 | PMID 40448572 Get It

PURPOSE Tumor treating fields (TTFields) use alternating electric fields to disrupt cancer cell proliferation. Feasibility of TTFields therapy with gemcitabine/nab-paclitaxel was previously demonstrated in patients with advanced pancreatic adenocarcinoma. PANOVA-3 was designed to confirm safety and efficacy of TTFields in patients with unresectable locally advanced pancreatic adenocarcinoma (LA-PAC). METHODS In this global phase III trial, 571 patients with newly diagnosed LA-PAC were randomly assigned to receive gemcitabine 1,000 mg/m 2 and nab-paclitaxel 125 mg/m 2 by intravenous infusion once a day on days 1, 8, and 15 of a 28-day cycle with or without TTFields. The primary end point was overall survival (OS). Secondary end points included progression-free survival (PFS), local PFS, pain-free survival, and overall response rate (ORR). Distant PFS was analyzed post hoc. RESULTS OS was significantly prolonged using TTFields with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel (median, 16.2 months [95% CI, 15.0 to 18.0] v 14.2 months [95% CI, 12.8 to 15.4]; hazard ratio [HR], 0.82 [95% CI, 0.68 to 0.99]; P = .039). PFS, local PFS, and ORR were not improved. Pain-free survival was significantly prolonged with TTFields with gemcitabine/nab-paclitaxel (median, 15.2 months [95% CI, 10.3 to 22.8] v 9.1 months [95% CI, 7.4 to 12.7]; HR, 0.74 [95% CI, 0.56 to 0.97]; P = .027), as was distant PFS (median, 13.9 months [95% CI, 12.2 to 16.8] v 11.5 months [95% CI, 10.4 to 12.9]; HR, 0.74 [95% CI, 0.57 to 0.96]; P = .022). Device-related skin adverse events (AEs) were experienced by 76.3% of patients. Most device-related skin AEs were mild to moderate, with 7.7% of patients reporting a grade 3 AE. CONCLUSION This study demonstrated significant OS, pain-free survival, and distant PFS benefits for TTFields with gemcitabine/nab-paclitaxel versus gemcitabine/nab-paclitaxel in patients with unresectable LA-PAC, with no additive systemic toxicity.
Treatment patterns and outcomes of head and neck cancer in sub-Saharan Africa: Insights from a multi-institutional cancer dataset.
Addison, Eric, Apamo, Primus, Manirakiza, Achille , Mina, Syeda A. , Truman, Matt, Bogan, Aaron, Mongare, Ben Roger, Dibaba, Yonas, Mwango, Gladys , Kemper, Katherine E. , Fekadu, Adugna, Merrell, Kenneth W. , Osei‐Bonsu, Ernest , Falade, Ayo , Dodoo, Christopher , Adjei, Ernest Kwasi , Woldetsadik, Edom Seife

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e18017 Get It

e18017 Background: Head and neck (H&N) cancers affect the oral cavity, pharynx, larynx, salivary glands, nasal cavity, and sinuses. In Sub-Saharan Africa (SSA), the true burden of H&N cancers remains unclear, with available estimates suggesting approximately 47,000 new cases and 26,000 deaths annually. Limited cancer datasets hinder understanding of disease patterns and outcomes. This study explores patient characteristics, treatments, and outcomes to guide regional cancer control efforts. Methods: A cancer dataset was created and implemented at 4 leading teaching hospitals in Ghana, Kenya, Ethiopia, and Rwanda to systematically collect data on patient demographics, disease characteristics, and treatment patterns. Established through competitive grant funding, the primary objective of the database was to assess the indirect impact of the COVID-19 pandemic on cancer care. The dataset includes all cancer patients seen in consultation and/or treated between 2016 and 2023. In this study, a subset of patients diagnosed with H&N cancers was analyzed using descriptive statistics to assess clinical characteristics, treatments modalities, and patients' outcomes. Results: A total of 1,023 patients with H&N cancer were included in the analysis. The median age at diagnosis was 54 yrs (IQR 41-66), with 37% (n= 374) of the cohort being female. A total of 55% (n= 549) had no health insurance coverage. Of those with staging data, majority presented with advanced disease (89%) on presentation. Regarding treatment modality, 16% (n= 157) underwent surgery, 27% (n=279) received radiotherapy (RT), 14% (n= 143) received chemotherapy (CT), and 56% (n= 572) received no cancer therapy. Of those who received CT the timing was neoadjuvant (12%), concurrent with RT (22%), adjuvant after surgery (8.9%) or as palliative treatment (57%). Platinum-based agents (94%) were the most common CT, followed by Taxol-based (31%), and 5FU-based agents (27%). Regarding RT, planning was performed using 2D (55%) and 3D (45%) techniques. The median delivered dose was 60 Gy in 30 fractions. At a median follow up of 43 months, 1.6% were disease free, 10% (n= 103) were alive, 5.9% (n= 60) were confirmed dead, and 84% (n= 848) were lost to follow up. Conclusions: This study identifies key challenges in managing H&N cancers in SSA, including late-stage presentation, limited access to advanced treatment modalities, and a high lost to follow-up rate (84%). The reliance on older RT techniques such as 2D planning and the limited use of surgery highlight gaps in infrastructure and resource availability. Limited health insurance coverage suggests potential financial barriers to care and disparities in treatment access. Addressing these challenges will require greater investment in cancer care, expansion of the oncology workforce, and improvements in healthcare infrastructure to support better patient outcomes in the region.
A molecular biomarker for longitudinal monitoring of therapeutic efficacy in a real-world cohort of advanced solid tumors treated with immune checkpoint inhibitors.
Guittar, John , Stein, Michelle M. , Chiou, Victoria L. , Nimeiri, Halla , Morgensztern, Daniel , Chaudhuri, Aadel A. , Zaidi, Ali Hussainy , Ben‐Shachar, Rotem

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: 2558-2558

10.1200/jco.2025.43.16_suppl.2558 Get It

2558 Background: Clinical validation studies have shown that early dynamic changes in circulating tumor DNA (ctDNA) tumor fraction (TF) can predict clinical outcomes. Yet few studies have evaluated the clinical value of longitudinal monitoring throughout the course of treatment. Here we evaluate longitudinal changes in ctDNA TF and clinical outcomes in an advanced real-world pan-cancer cohort of patients (pts) treated with immune checkpoint inhibitors (ICIs). Methods: The cohort included deidentified pts from the Tempus clinicogenomic database with stage IIIB or IV solid tumors who underwent ctDNA NGS and were treated with an FDA-approved ICI +/- chemotherapy (CT). Pts had a pre-treatment baseline liquid biopsy (T0) and ≥1 on-treatment sample Ti within 21-180 days of ICI. xM for treatment response monitoring estimates TF via an ensemble algorithm that incorporates variant and copy number information. Response status was determined at each on-treatment timepoint Ti relative to T0. Pts were classified as a Molecular Responder (MR) if TF < 1% at T0 and Ti or if TF decreased by ≥ 50% from T0 to Ti; otherwise, they were classified as a Molecular Non-Responder (nMR). Pts with TF < 0.09% at T0 and Ti were classified as ctDNA not detected. The longitudinal cohort included pts with ≥2 on-treatment timepoints, further classified based on the most frequent classification across each Ti as longitudinal MR, longitudinal nMR and longitudinal ctDNA not detected. If no classification was dominant, the most recent classification was used. Real-world overall survival (rwOS) was defined from T1 to death and assessed by log-rank test. Results: The full cohort of 84 pts with > 10 solid tumors included 34.5% (n = 29) NSCLC and 16.7% (n = 14) SCLC. The majority of pts (59.5%, n = 50) received ICI+CT, (64.0% first-line [1L]), and 40.5% (n = 34) ICI-only (35.3% 1L). rwOS was longer for 53 MRs vs. 18 nMRs (median not reached vs. 7.0 months, P < 0.005); 13 pts had no ctDNA detected. The longitudinal subcohort of 35 pts was 31.4% (n = 11) NSCLC, 20.0% (n = 7) prostate cancer, and 14.3% (n = 5) SCLC; 45.7% (n = 16) ICI+CT (56.3% 1L), 54.3% (n = 19) ICI-only (31.6% 1L). On average, pts had 3 on-treatment liquid biopsies, with a median time between on-treatment samples of 91 days. Twelve pts were longitudinal nMRs (10 MR or ctDNA not detected at T1), 18 longitudinal MRs, and 5 longitudinal no ctDNA detected. There were 6 death events in the longitudinal nMRs, 3 in the longitudinal MRs (all > 18 months after T1), and no death events in the longitudinal no ctDNA detected group. Longitudinal MRs had longer rwOS than longitudinal nMRs (median 37.4 months vs 8.7 months, P < 0.005). Conclusions: Longitudinal nMR was associated with worse survival compared to longitudinal MR. Longitudinal, molecular biomarker dynamics may be a useful clinical treatment decision tool for monitoring treatment response to ICI therapy.
Cancer–heart cross talk: Cytokine release pattern from anthracycline-treated cancer cell lines and their impact on cardiomyocyte metabolism.
Copley, E A , Herrmann, Joerg, Lerman, Ben , Zhang, Song , Kloeber, Jake A. , Lou, Zhenkun , Morse, David , Herrmann, Joerg

Mayo Clinic

Journal of Clinical Oncology | May 28, 2025 | Volume: 43 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2025.43.16_suppl.e24015 Get It

e24015 Background: Anthracyclines are effective cancer therapeutics but can cause cardiotoxicity. Recent studies suggest a connection between efficacy and toxicity in that the effects of anthracyclines on cancer cells leads to the release of interleukin 1-alpha (IL-1⍺), which negatively impacts cardiomyocyte metabolism and thereby cardiac function. This observation was made in in vivo and in vitro models of acute myeloid leukemia (AML); whether this holds true for other cancer cell lines remains unclear. Methods: Herein we characterized the cytokine profile of 9 cancer cell lines exposed to doxorubicin (1 µM for 24 hours) and then tested the effects of interleukin 1-alpha (IL-1⍺, 50-150 ng/mL) on the viability and metabolism of neonatal cardiomyocyte. We used Seahorse to assess cardiomyocyte glycolysis via extracellular acidification rate (ECAR) and mitochondrial oxidative phosphorylation based on the oxygen consumption rate (OCR). Results: As outlined in Table 1, different hematological and breast cancer cell lines showed a range of cytokine profile in response to doxorubicin exposure. Of the cytokines with putative action on cardiomyocyte metabolism IL-1⍺was one of the most induced in 3 out of 5 murine breast cancer, murine B- and T-cell lymphoma, as well as murine and human AML human and murine cell lines. Doxorubicin did not induce IL-1⍺ expression in macrophage cell lines (RAW) or directly in cardiomyocytes. Exposing neonatal cardiomyocytes to different concentrations of IL-1⍺ did not decrease but rather increased OCR and especially ECAR. Conclusions: These data confirm the release of IL-1⍺ from AML as well as several, but not all breast cancer cell lines. Furthermore, purified IL-1⍺ increased oxidative phosphorylation and glycolysis in murine neonatal cardiomyocytes. These data point out heterogeneity in the cytokine release pattern from anthracycline-treated cancer cell lines and their impact on cardiomyocyte metabolism. Further studies are required to define the nuances of crosstalk between cancer and the heart and its contribution to the variation in cardiotoxicity risk. Cytokine profile of cancer cell lines. Cytokines RAW Neonatal MC38HuPD-L1 EMT6 JC E0771 4T1 B Lymphoma: A20 T Lymphoma: E.G7-OVA AML Human: THP-1 AML mouse: C1498 ICAM-1, CD54 ++ ++ ++ ++ ++ ++ IL-1α IL-1F1 + + + + + + + IL-10 + + IL-16 ++ ++ ++ CXCL10/CRG-2 ++ + ++ ++ ++ ++ ++ ++ ++ M-CSF ++ ++ ++ + ++ ++ ++ ++ + RANTES CCL5 + ++ ++ ++ ++ TNF-α +++ + ++ + + + + +
Differentiation-dependent EBF1 activity determines CD22 transcription and leukemia sensitivity to inotuzumab ozogamicin
Escherich, Carolin S. , Li, Zhenhua , Li, Yizhen , Walker, Megan, Yoshimura, Satoshi , Yang, Wenjian , Huang, Xin , Yu, Jiyang , Paietta, Elisabeth , Konopleva, Marina , Jabbour, Elias, Litzow, Mark R. , Inaba, Hiroto , Evans, William E. , Savic, Daniel , Li, Yizhen , Yang, Wenjian , Huang, Xin , Yu, Jiyang , Konopleva, Marina , Litzow, Mark R. , Pui, Ching-Hon , Loh, Mignon L , Inaba, Hiroto , Escherich, Carolin , Barnett, Kelly R. , Stock, Wendy , Kornblau, Steven M. , Jabbour, Elias , Loh, Mignon L. , Yang, Jun

Mayo Clinic

Blood | May 28, 2025 | Volume: 146 | Issue: 4 | Pages: 471-481

10.1182/blood.2024028215 | PMID 40435412 Get It

Abstract Inotuzumab ozogamicin (InO) is an antibody-calicheamicin conjugate with high efficacy in lymphoid malignancies. It targets the B-cell surface protein CD22, which is expressed in most B-cell acute lymphoblastic leukemia (B-ALL) cases, albeit with variable intensity. However, factors governing CD22 expression and thus leukemia sensitivity to InO remain incompletely understood. Using multiomic characterization of 196 human B-ALL samples, coupled with ex vivo InO sensitivity profiling, we showed that early leukemia differentiation arrest at the pre–pro-B stage is associated with resistance to InO. Screening of 1639 transcription factor genes identified early B-cell factor 1 (EBF1) as a key regulator of CD22 expression (false discovery rate of 7.1 × 10−4). When comparing the assay for transposase-accessible chromatin with sequencing profiling results of the most InO-sensitive and -resistant cases (50% lethal concentration &lt;10th vs &gt;90th percentile, n = 18), the binding motif for EBF1 was strikingly enriched in regions with differential open chromatin status (P = 8 × 10−174). CRISPR interference targeting EBF1 binding sites at the CD22 locus led to an ∼50-fold reduction in cell surface CD22 expression and, consequently, an ∼22-fold increase in InO resistance in ALL cell lines. Interestingly, within BCR::ABL1 ALL, we observed intrasubtype heterogeneity linked to EBF1 transcriptional downregulation (P = 1.1 × 10−15) and/or somatic alteration (P = .004), which led to reduced CD22 expression (P = 8.3 × 10−11) and ex vivo and in vivo resistance to InO. Collectively, these findings point to the direct impact of EBF1 on CD22 expression during B-cell development, which, in turn, contributes to interpatient variability in InO response, even within the same subtype of B-ALL.